Q2 Fiscal Year 2022
- Continued very good growth in orders and revenue in the second quarter: equipment book-to-bill ratio of 1.22 and comparable revenue growth of 15.8%
- Diagnostics achieved outstanding comparable revenue growth of 37.2%; revenue of almost €680 million from rapid COVID-19 antigen tests
- Substantial comparable revenue growth of 6.5% in Imaging and 7.6% in Advanced Therapies
- Varian with a revenue contribution of €706 million and a strong equipment book-to-bill ratio of 1.31
- Adjusted EBIT margin of 17.9% due to higher contributions from rapid COVID-19 antigen tests; currency effects and higher procurement and logistics costs had a negative impact
- Adjusted basic earnings per share up 53% to €0.67
Updated Outlook for Fiscal Year 2022
Due to the further increased demand for rapid COVID-19 antigen tests, we again raise our outlook for fiscal year 2022. The outlook is now based on the assumption that the Diagnostics segment will generate around €1.3 billion (previously around €700 million) in revenue with rapid COVID-19 antigen tests. As a result, we now expect comparable revenue growth between 5.5% and 7.5% (previously 3% to 5%) and adjusted basic earnings per share between €2.25 and €2.35 (previously €2.18 to €2.30).
Bernd Montag, CEO of Siemens Healthineers AG:
»Our purpose is to pioneer breakthroughs in healthcare for everyone, everywhere – especially in times like these. Our business continues to show great resilience in the face of unprecedented challenges. On this foundation, and thanks to high demand for our rapid antigen tests, we are raising our outlook for the current financial year.«